Cellseed Inc. · TSE:7776

Cellseed — H1 2021 Earnings Presentation

26 slides from Cellseed's earnings presentation, Aug 20, 2021

Slide 1: Fiscal 2021 First-Half Earnings Results Presentation
CellSeed Inc. Fiscal 2021First-Half Earnings Results Presentation Stock Code:7776
Slide 3: CellSeed Inc. Corporate Information
CellSeed Inc. Corporate Information Established May, 2001 Core competence Cell Sheet Engineering based on Temperature Responsive Polymers Listed JASDAQ（7776) in 2010 Business Regenerative Medical Regenerative Medicine Products Business Supporting Business • Commercialization of Cell Sheet Therapies
Slide 4: 20th anniversary of the foundation of CellSeed
20th anniversary of the foundation of CellSeed 2018 2020 2021 Start of regenerative Establishment of joint 20th anniversary medicine contract venture in Taiwan of the foundation of services CellSeed 2017 2016 2015 • Approval to manufacture • Head office relocation to the CellSeed Sweden AB specified
Slide 5: Our Business Model
Our Business Model Mission We take the initiative of contributing to global health care in the valuable and innovative field of regenerative medicine. Medical Hospitals Seeds Products Patients Treatment University Base of Innovation Collaborative Fee Medical Research Expenses Business Alliance Partn
Slide 8: Half-year financial summary FY 12/2021
Half-year financial summary FY 12/2021 First Half of the FY2020 First Half of the FY2021 Consolidated Consolidated （January 2021 - June 2021）（January 2020 - June 2020） Change from Amount Change Amount Previous Period （Millions of Yen）（Millions of Yen）（Millions of Yen）（%） Net sales 81 23 39.9 58
Slide 9: Differences between the estimates and results in the second quarter of the term ending Dec. 2021
Differences between the estimates and results in the second quarter of the term ending Dec. 2021 [unit: million yen, rounded down to the nearest million] Operating Ordinary Profit attributable to Net sales profit profit owners of parent Previously announced estimates (announced on Feb. 14, 2021) 50
Slide 11: Cell cultureware in the regenerative medicine supporting business
Cell cultureware in the regenerative medicine supporting business Professor Okano of Tokyo Women’s Medical Temperature-responsive cell cultureware 1989 University invented temperature-responsive cell cultureware. invented by Professor Okano of Tokyo Women's Medical University in 1989 can 2004 Releas
Slide 12: CellSeed Temperature Sensitive Cell Cultureware Lineup
CellSeed Temperature Sensitive Cell Cultureware Lineup UpCell® RepCell ® HydroCell ® Cell Sheet Recovery Cell Recovery Ultra-Low Adhesion Cell （Temperature Sensitive）（Temperature Sensitive） Cultureware  Temperature-responsive  Temperature-responsive  Low cell binding cell cultureware for "Cell c
Slide 13: Cultivation of new markets for cell cultureware
Cultivation of new markets for cell cultureware Recently, the production of bio-pharmaceutical products using mass-cultured cells, the immunotherapy using cells, and initiatives for solving food and environmental issues have been active. In the generally used cell collection technology, proteolytic
Slide 14: System for enhancing the sales of devices
System for enhancing the sales of devices In order to expand overseas sales channels, we will strengthen our sales structure. In addition, in order to offer consistent quality and services and satisfy customers further, we developed a quality management system and obtained the international certific
Slide 15: Establishment of development and manufacturing facilities
Establishment of development and manufacturing facilities In response to the growth of overseas sales volume, we decided to construct facilities for developing and manufacturing cell cultureware. We plan to start the operation of the facilities in the 4th quarter of FY12/21.  Outline of facilities
Slide 16: Regenerative Medicine Supporting Business
Regenerative Medicine Supporting Business Development of Manufacturing Methods and 1 Contract Manufacturing for Cell Sheet Products  Development of cell sheet manufacturing methods  Contract manufacturing of cell sheet products  Quality testing of cell sheets, etc. Facility Management and Applica
Slide 17: Commissioned projects in our regenerative medicine service
Commissioned projects in our regenerative medicine service For the regenerative medicine service, we obtained the permission to manufacture specific processed cells (facility No. FA3160008) in March 2017 and the permission to manufacture products for regenerative medicine in October 2018 and have un
Slide 18: Chondrocyte Sheet
Chondrocyte Sheet  Disease characteristics • Causes︓ageing・obesity traumatic • No treatment to regenerate lost cartilage is available  In Japan, estimated number of potential patients about 30 million persons of which, about 10 million shows symptoms. Go Omori, Yoshio Koga and others From epidemio
Slide 19: Overview of Chondrocyte Sheet Project
Overview of Chondrocyte Sheet Project  Clinical Research at University Tokai University School of Medicine Prof. Masato Sato, School of Medicine, Tokai University Started medial treatment in ＜Autologous Cartilage Sheets＞ • 2010 Clinical study started, 8 cases Tokai University completed as Advanced
Slide 20: Allogeneic chondrocyte sheets: Quality/Safety
Allogeneic chondrocyte sheets Preparation of Cell Stock Master Working Cell Cell Bank Bank Cell Suspension Culture Evaluation test Quality/Safety In liq.Nitrogen In liq.Nitrogen Transport- ation Polydactyly donors Collection of tissue Manufacture Packaging Lot release test Thawing Culture CellSheet
Slide 21: Allogeneic chondrocyte sheets
Allogeneic chondrocyte sheets Clinical Research at Tokai University Completed in December 2019 transplants of 10 cases Development at Transfer of the cell bank and cell sheet manufacturing CellSeed technology from Tokai University to CellSeed Sep. 2018 Adopted as “a project for developing fundamenta
Slide 22: Epithelial Cell Sheet for Esophageal Regeneration
Epithelial Cell Sheet for Esophageal Regeneration (CLS2702C/D)  A medical treatment developed by Tokyo Womenʼs Medical University as a regenerative treatment for esophageal cancer (to heal esophageal wound and prevent stricture)  Cell sheet is on a temperature-responsive cell culture ware and then
Slide 23: Clinical Research and Clinical Trials of Esophageal Cell Sheet
Clinical Research and Clinical Trials of Esophageal Cell Sheet Tokyo Women’s Medical University  Clinical Research at Universities 2008－2014＜Japan＞ Tokyo Womenʼs Medical Univ. 10case Tokyo Womenʼs Medical Univ. Basic 10case Development and Nagasaki Univ. Agreement ＜Europe＞ Karolinska University Hos
Slide 24: The 2nd Cell Sheet Engineering Innovation Forum
The 2nd Cell Sheet Engineering Innovation Forum We plan to stream the 2nd forum on cell sheet engineering innovation live on Nov. 1, 2021. • Speakers Tatsuya Shimizu, Ph,D., M.D. Professor, Tokyo Womenʼs Medical University, Director, Institute of Advanced BioMedical Engineering and Science Yuji Miya
Slide 25: The 19th share acquisition right exercised
The 19th share acquisition right with a provision for revising exercise price exercised All of the 19th share acquisition rights issued on August 6, 2020 to Barclays Bank PLC were exercised on July 29, 2021. Exercise price 211-327 yen/share No. of share acquisition rights exercised 35,000 Exercised
Slide 26: This presentation is made by CellSeed Inc. solely for the disclosure of the financial
This presentation is made by CellSeed Inc. solely for the disclosure of the financial statements, and not published for the purpose of soliciting sales or purchases of securities in Japan and any other regions. Copyright © 2020 CellSeed Inc. All Rights Reserved.

CellSeed — H1 2021 Earnings Presentation on 6ix

Cellseed — H1 2021 Earnings Presentation

Slide 1: Fiscal 2021 First-Half Earnings Results Presentation

Slide 2: Contents

Slide 3: CellSeed Inc. Corporate Information

Slide 4: 20th anniversary of the foundation of CellSeed

Slide 5: Our Business Model

Slide 6: Development of Treatment Using Cell Sheet Engineering

Slide 7: Contents

Slide 8: Half-year financial summary FY 12/2021

Slide 9: Differences between the estimates and results in the second quarter of the term ending Dec. 2021

Slide 10: Contents

Slide 11: Cell cultureware in the regenerative medicine supporting business

Slide 12: CellSeed Temperature Sensitive Cell Cultureware Lineup

Slide 13: Cultivation of new markets for cell cultureware

Slide 14: System for enhancing the sales of devices

Slide 15: Establishment of development and manufacturing facilities

Slide 16: Regenerative Medicine Supporting Business

Slide 17: Commissioned projects in our regenerative medicine service

Slide 18: Chondrocyte Sheet

Slide 19: Overview of Chondrocyte Sheet Project

Slide 20: Allogeneic chondrocyte sheets: Quality/Safety

Slide 21: Allogeneic chondrocyte sheets

Slide 22: Epithelial Cell Sheet for Esophageal Regeneration

Slide 23: Clinical Research and Clinical Trials of Esophageal Cell Sheet

Slide 24: The 2nd Cell Sheet Engineering Innovation Forum

Slide 25: The 19th share acquisition right exercised

Slide 26: This presentation is made by CellSeed Inc. solely for the disclosure of the financial